Table 1.
Characteristics of Patients with Advanced Lung Adenocarcinomas
| No. of Patients (%) | EGFR Mutational Status | p value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| All | 134 (100) | 72 (54) | 62 (46) | |
| Gender | 0.046 | |||
| Female | 45 (34) | 13 (18) | 32 (52) | |
| Male | 89 (66) | 59 (82) | 30 (47) | |
| Age, yrs | 0.883 | |||
| <65 | 67 (50) | 39 (54) | 28 (45) | |
| ≥65 | 67 (50) | 33 (46) | 34 (55) | |
| Smoking | 0.017 | |||
| Never | 58 (43) | 20 (28) | 38 (61) | |
| Ever | 76 (57) | 52 (72) | 24 (39) | |
| ECOG performance status | 0.829 | |||
| 0,1 | 108 (80) | 57 (80) | 51 (82) | |
| ≥2 | 26 (20) | 15 (20) | 11 (18) | |
| Tumor size, cm | 0.747 | |||
| <3 | 67 (50) | 32 (44) | 35 (56) | |
| ≥3 | 67 (50) | 40 (56) | 27 (44) | |
| Stage | 1.000 | |||
| IIIB | 9 (7) | 4 (6) | 5 (8) | |
| IV | 125 (93) | 68 (94) | 57 (92) | |
| Metastatic organs | 0.937 | |||
| 0–2 | 106 (80) | 58 (81) | 48 (79) | |
| ≥3 | 28 (20) | 16 (19) | 14 (21) | |
| Brain metastasis | 0.776 | |||
| No | 95 (71) | 47 (65) | 48 (79) | |
| Yes | 39 (29) | 25 (35) | 14 (21) | |
| Liver metastasis | 0.641 | |||
| No | 112 (84) | 57 (79) | 55 (88) | |
| Yes | 22 (16) | 15 (21) | 7 (12) | |
| EGFR subtype | – | |||
| Exon19 deletion | 35 (26) | – | 35 (57) | |
| L858R mutation | 25 (18) | – | 25 (47) | |
| Other sites | 2 (1) | – | 2 (3) | |
| First-line regimen | - | |||
| Pemetrexed/platinum | 72 (54) | 72 (100) | - | |
| Gefitinib | 3 (2) | - | 3 (5) | |
| Erlotinib | 4 (3) | - | 4 (6) | |
| Afatinib | 55 (41) | - | 55 (81) | |
| SUVmax | 0.010 | |||
| Low (<9.6) | 40 (30) | 30 (42) | 52 (84) | |
| High (≥9.6) | 94 (70) | 42 (58) | 10 (16) | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; SUVmax, maximal standardized uptake value.